Article

CCI For Combination Products: Assembling The Package Integrity Profile For Autoinjectors

Source: PTI Packaging and Inspection Systems

By Brandon Zurawlow, Principal Consultant at Containsure

Insulin pen 450x300

Due to their complexity, combination products, specifically autoinjection systems, present unique challenges in implementing a container closure integrity (CCI) testing strategy. This is further complicated by a pervasive, though diminishing, tendency for companies to consider CCI only at the final product-package lifecycle stage, an approach where combination products will highlight the pitfalls. This article seeks to discuss the unique challenges of CCIT on combination products, and how to overcome them using a modern, risk management approach to CCI in line with current guidance and regulation: development of a package integrity profile.

access the Article!

Get unlimited access to:

Trend and Thought Leadership Articles
Case Studies & White Papers
Extensive Product Database
Members-Only Premium Content
Welcome Back! Please Log In to Continue. X

Enter your credentials below to log in. Not yet a member of Pharmaceutical Online? Subscribe today.

Subscribe to Pharmaceutical Online X

Please enter your email address and create a password to access the full content, Or log in to your account to continue.

or

Subscribe to Pharmaceutical Online

PTI Packaging and Inspection Systems